We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Agronomics Limited | LSE:ANIC | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.40 | 5.00% | 8.40 | 8.10 | 8.40 | 8.25 | 8.00 | 8.00 | 1,211,081 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investors, Nec | 30.88M | 22.37M | 0.0222 | 3.72 | 83.28M |
TIDMANIC
RNS Number : 3706S
Agronomics Limited
14 July 2022
14(th) July 2022
Agronomics Limited
("Agronomics" or the "Company")
Appointment of Joint Corporate Broker
Agronomics Limited (AIM:ANIC), a leading listed company focused on cellular agriculture, is pleased to announce the appointment of Canaccord Genuity Limited ("Canaccord") as its Joint Corporate Broker with immediate effect.
For further information please contact:
Agronomics Beaumont Canaccord Cenkos Peterhouse TB Cardew Limited Cornish Genuity Limited Securities Capital Limited Plc Limited The Company Nomad Joint Broker Joint Broker Joint Broker Public Relations ================ =================== =============== =============== ===================== Richard Roland Cornish Andrew Potts Giles Balleny Lucy Williams Ed Orlebar Reed James Biddle Harry Rees Michael Charles Charlotte Denham Eke Alex Aylen Johnson Goodfellow Anderson (Head of Equities) ================ =================== =============== =============== ===================== +44 (0) 20 7930 0777 +44 (0) 7738 +44 (0) +44 (0) +44 (0) +44 (0) 724 630 1624 639396 207 628 +44 (0) 207 207 397 207 469 agronomics@tbcardew.c info@agronomics.im 3396 523 8000 8900 0936 om ================ =================== =============== =============== =====================
About Agronomics
Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 22 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.
About Cellular Agriculture
Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.
Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5
AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 4 billion has been invested worldwide since the industry's inception in 2016.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCLXLFFLDLXBBZ
(END) Dow Jones Newswires
July 14, 2022 02:00 ET (06:00 GMT)
1 Year Agronomics Chart |
1 Month Agronomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions